Genmab — Juni 2025
-
-
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S
) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL
-01 Trial https://ir.genmab.com/news-releases/news-release-details/genmab-announces-investigational-rinatabart-sesutecan-rina-sr -
Det ser lovende ud, især med en objektiv responsrate på 50 % og to komplette responser i en svært forbehandlet gruppe med fremskreden endometriecancer. At median responsvarighed ikke er nået efter 7,7 måneders opfølgning ser - som Legolas nævner - godt ud.
-
not sure if this is AI generated...- Genmab's Rina-S
: A Breakthrough in Endometrial Cancer with Massive Commercial Potential https://www.ainvest.com/news/genmab-s-rina-s-a-breakthrough-in-endometrial-cancer-with-massive-commercial-potential-2506101098c313ec4f77eaa7/ -
AI or not. That's a screaming buy recommendation. You should always be careful with that in the early phase.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind